AKBA News and Press, Akebia Therapeutics Inc. From 03/11/24

Akebia Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results PR Newswire CAMBRIDGE, Mass. , March 11, 2024 /PRNewswire/ -- Akebia Therapeutics ® , Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to b...

2024-01-30 08:30:12 ET More on Akebia Akebia Therapeutics, Inc. (AKBA) Q3 2023 Earnings Call Transcript Akebia Therapeutics: Waiting For Round 2 Akebia Q3 2023 Earnings Preview Seeking Alpha’s Quant Rating on Akebia Historical earnings data for...

Akebia Secures $55 Million Term Loan Financing PR Newswire Strengthens Balance Sheet Ahead of Potential Vadadustat Approval on March 27, 2024 CAMBRIDGE, Mass. , Jan. 30, 2024 /PRNewswire/ -- Akebia Therapeutics ® , Inc. (Nasda...

Akebia Therapeutics Announces Appointment of Nicholas Grund as Chief Commercial Officer PR Newswire CAMBRIDGE, Mass. , Jan. 9, 2024 /PRNewswire/ -- Akebia Therapeutics ® , Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose ...

Akebia Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference PR Newswire CAMBRIDGE, Mass. , Dec. 20, 2023 /PRNewswire/ -- Akebia Therapeutics ® , Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to ...

Akebia Therapeutics to Present at Piper Sandler Healthcare Conference PR Newswire CAMBRIDGE, Mass. , Nov. 20, 2023 /PRNewswire/ -- Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by...

2023-11-08 14:18:02 ET Akebia Therapeutics, Inc. (AKBA) Q3 2023 Earnings Conference Call November 08, 2023 08:00 AM ET Company Participants Mercedes Carrasco - Senior Director of Corporate Communications and IR John Butler - President and CEO Ellen Snow - SVP and...

2023-11-08 07:33:40 ET More on Akebia Akebia Therapeutics: Waiting For Round 2 Akebia Therapeutics, Inc. (AKBA) Q2 2023 Earnings Call Transcript Akebia Q3 2023 Earnings Preview Akebia kidney disease therapy undergoes FDA review again Seeking Alpha...

Akebia Therapeutics Reports Third Quarter 2023 Financial Results and Recent Business Highlights PR Newswire Akebia to host conference call at 8:00 a.m. ET Vadadustat NDA assigned a PDUFA date of March 27, 2024 Vadadustat approved in 36 countries, including ...

Evotec SE (EVO) is expected to report $-0.03 for Q3 2023 Amplifon (AMFPF) is expected to report for Q3 2023 Compass Therapeutics Inc. (CMPX) is expected to report $-0.11 for Q3 2023 Astronics Corp. - Class B (ATROB) is expected to report for Q4 2023 Charge Enterprises Inc. (CRGE) ...